Movement Alert｜Agilent Technologies Rises 6.77% in Pre-Market Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised

Market Focus

May 28

On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.

The rally was driven by strong fiscal Q2 results and an upward revision to full-year guidance. Agilent reported adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion and growing approximately 10.2% year-over-year. The company raised its full-year adjusted EPS outlook to $6.00–$6.10, up from the prior range of $5.90–$6.04, citing strong demand for laboratory research and diagnostic tools. Management highlighted GLP-1 drug momentum as a key growth driver, contributing roughly 20% growth year-to-date. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum across key instrument platforms and tailwinds from US pharmaceutical reshoring.

Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1112361543"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112361543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112361543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 16:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112361543","market":"us","top_or_hot":-1,"title":"Movement Alert｜Agilent Technologies Rises 6.77% in Pre-Market Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.</p><p>The rally was driven by strong fiscal Q2 results and an upward revision to full-year guidance. Agilent reported adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion and growing approximately 10.2% year-over-year. The company raised its full-year adjusted EPS outlook to $6.00–$6.10, up from the prior range of $5.90–$6.04, citing strong demand for laboratory research and diagnostic tools. Management highlighted GLP-1 drug momentum as a key growth driver, contributing roughly 20% growth year-to-date. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum across key instrument platforms and tailwinds from US pharmaceutical reshoring.</p><p>Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Agilent Technologies Rises 6.77% in Pre-Market Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Agilent Technologies Rises 6.77% in Pre-Market Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 16:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.</p><p>The rally was driven by strong fiscal Q2 results and an upward revision to full-year guidance. Agilent reported adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion and growing approximately 10.2% year-over-year. The company raised its full-year adjusted EPS outlook to $6.00–$6.10, up from the prior range of $5.90–$6.04, citing strong demand for laboratory research and diagnostic tools. Management highlighted GLP-1 drug momentum as a key growth driver, contributing roughly 20% growth year-to-date. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum across key instrument platforms and tailwinds from US pharmaceutical reshoring.</p><p>Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"A","symbol_name":"安捷伦科技","start_time":0,"source_url":"","article_id":"1112361543","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112361543","pubTimestamp":1779955759,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.The rally was driven by strong fiscal Q2 results and an upward revision to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"A":"安捷伦科技"},"translate_title":"动向提示|安捷伦科技盘前涨6.77%Q2盈利超预期上调全年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1},"content_text":"On May 28, Agilent Technologies rose 6.77% in pre-market trading, trading at $122.73/share, with trading volume of $16,500.The rally was driven by strong fiscal Q2 results and an upward revision to full-year guidance. Agilent reported adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion, surpassing the expected $1.799 billion and growing approximately 10.2% year-over-year. The company raised its full-year adjusted EPS outlook to $6.00–$6.10, up from the prior range of $5.90–$6.04, citing strong demand for laboratory research and diagnostic tools. Management highlighted GLP-1 drug momentum as a key growth driver, contributing roughly 20% growth year-to-date. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, citing product cycle momentum across key instrument platforms and tailwinds from US pharmaceutical reshoring.Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables for laboratory workflows.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}